DFTX vs KLRA: Which Stock Is the Better Buy?
Definium Therapeutics, Inc. and Kailera Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — DFTX vs KLRA, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Definium Therapeutics, Inc. (DFTX) | Kailera Therapeutics, Inc. (KLRA) | |
|---|---|---|
| Market cap | $2.6B | $2.6B |
| Revenue (latest FY) | $0 | $0 |
| Net income (latest FY) | $-183.79M | $-148.96M |
| Revenue growth (5y CAGR) | — | — |
| Net margin | — | — |
| Return on equity | -55.3% | 41.8% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | — | No |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full DFTX vs KLRA breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open DFTX's full financials → Open KLRA's full financials →More comparisons
Frequently asked questions
Which is bigger, DFTX or KLRA?
Definium Therapeutics, Inc. is larger by market capitalization — $2.6B versus $2.6B.
Which grows faster, DFTX or KLRA?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
DFTX fundamentals → · KLRA fundamentals → · All 1,500+ companies → · Free screener →